Abstract
Following the recognition that angiogenesis is essential for tumor growth and metastasis formation (1,2), evidence has accumulated that angiogenesis is a component of many pathologies. Numerous angiogenic factors that regulate this complex process alone or in synergy have been identified. Vascular endothelial growth factor (VEGF) (3), basic fibroblast growth factor (bFGF) (4), transforming growth factor-α (TGF-α), platelet-derived growth factor (PDGF), and angiopoietin-1 and -2 (Ang-1 and Ang-2) have been shown to induce angiogenesis in a variety of experimental models (5-7). VEGF is an important angiogenic agent and endothelial specific mitogen, which has been implicated in the neovascularization of a wide variety of tumors (9). VEGF acts via a paracrine mechanism mainly through two specific receptors on the surface of endothelial cells: Flt 1 and KDR (10,11). Although encoded by a single gene, VEGF has several isoforms generated by alternative splicing (12,13). Of these, the main isoforms VEGF121 and VEGF165 are secreted soluble glycoproteins, whereas VEGF189 and VEGF206 remain bound to heparan sulfate proteoglycans at the cell surface (14). The importance of VEGF as a potential target for antineoplastic therapy has been demonstrated in several studies in which neutralizing antibodies to VEGF or VEGF receptors inhibited tumor growth and vascularization in vivo (15,16).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Folkman, J. (1986) How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res. 46, 467–473.
Folkman, J. (1989) What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4–6.
Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1309.
Folkman, J. and Klagsbrun, M. (1987) Angiogenic factors. Science 235, 442–447.
Rappolee, D. A., Mark, D., Banda, M. J., and Werb, Z. (1991) Wound macrophages express TGF-α and other growth factors in vivo: analysis by mRNA phenotyping Science 241, 708–712.
Risau, W., Drexler H., Mironov V., Smits, A., Siegbahn, A., Funa, K., et al. (1992) Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7, 261–266.
Suri C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., et al.(1996) Requisite role of angiopoietin-1, a ligand for the tie-2 receptor, during embryonic angiogenesis. Cell 87, 1171–1180.
Smith, K., Fox, S. B., Whitehouse, R., Taylor, M., Greenall, M., Clarke, J., et al.(1999) Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann. Oncol. 10, 707–713.
Plate, K. H., Breier, G., Weich, H. A., and Risau, W. (1992) Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359, 845–848.
de Vries, C., Escobido, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989–991.
Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., et al. (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem. Biophys. Res. Commun. 187, 1579–1586.
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., et al. (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11,947–11,954.
Neufeld, G., Tessler, S., Gitay-Goren, H., Cohen, T., and Levi, B. Z. (1994) Vascular endothelial growth factor and its receptors. Prog. Growth Factor Res. 5, 89–97.
Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., and Ferrara, N. (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26,031–26,037.
Asano, M., Yukita, A., Matsumoto, T., Kondo, S., and Suzuki, H. (1995) Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res. 55, 5296–5301.
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Philipps, H. S., et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844.
Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., et al. (1996) Vascular endothelial growth factor B, a novel growth factor for endothelial cells. PNAS 93, 2576–2581.
Olofsson, B., Pajusola, K., von Euler, G., Chilov, D., Alitalo, K., and Eriksson, U. (1996) Genomic organisation of the mouse and human genes for vascular endothelial growth factor B (VEGF B) and characterization of a second splice isoform. J. Biol. Chem. 271, 19,310–19,317.
Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., et al.(1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR(VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 290–298.
Kaipainen, A., Korhonen, J., Mustonen, T., van Hinsbergh, V. W., Fang, G. H., Dumont, D., et al. (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Nat l. Acad. Sci. 92, 3566-3570.
Salven, P., Lymboussaki, A., Heikkila, P., Jaaskela-Saari, H., Enholm, B., Aase, K., et al. (1998) Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am. J. Pathol. 153, 103–108.
Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., et al. (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192–198.
Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., et al. (1996) Isolation of angiopoietin-1, a ligand for the tie-2 receptor, by secretion-trap expression cloning. Cell 87, 1161–1169.
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., et al. (1997) Angiopoietin-2, a natural antagonist for tie-2, that disrupts in vivo angiogenesis. Science 277, 55–60.
Hanahan, D. (1997) Signaling vascular morphogenesis and maintenance. Science 277, 48–50.
Schweigerer, L., Neufeld, G., Friedman, J., Abraham, J. A., Fiddes, J. C., and Gospodarowicz, D. (1987) Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325, 257–259.
Heldin, C.-H. (1992) Structural and functional studies on platelet-derived growth factor. EMBO J. 11, 4251–4259.
Ross, R., Raines, E. W., and Bowen-Pope, D. F. (1986) The biology of plateletderived growth factor. Cell 46, 155–169.
Gille, J., Swerlick, R. A., and Caughman, S. W. (1997) Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation EMBO J. 18, 50–59.
Ciardiello, F., Kim, N., McGeady, M. L., Liscia, D. S., Saeki, T., Bianco, C., et al. (1991) Expression of transforming growth factor α (TGFα) in breast cancer. Ann. Oncol. 2, 169–182.
Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1–8.
Parums, D. V., Cordell, J. L., Micklem, K., Heryet, A. R., Gatter, K. C., and Mason, D. Y. (1990) JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J. Clin. Pathol. vbn43, 752–757.
Li, V. W., Folkerth, R. D., Watanabe, H., Yu, C., Rupnick, M., Barnes, P., et al. (1994) Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 344, 82–86.
Hayes, C. E. and Goldstein, I. J. (1974) An alpha-D-galactosyl-binding lectin from Bandeiraea simplicifolia seeds. Isolation by affinity chromatography and characterization. J. Biol. Chem. 249, 1904–1914.
Malinda, K. M. (2000) In vivo Matrigel migration and angiogenesis assays, in Angiogenesis Protocols (Murray, J. C., ed.), Humana, Totowa, NJ, pp. 47–53.
Wang, G. L. and Semenza, G. L. (1993) Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82, 3610–3615.
Kwiatkowski, J. L., Rutkowski, J. L., Yamashiro, D. J., Tennekoon, G. I., and Brodeur, G. M. (1998) Schwann cell-conditioned medium promotes neuroblastoma survival and differentiation. Cancer Res. 58, 4602–4606.
Eggert, A., Grotzer, M. A., Ikegaki, N., Liu, X. G., Evans, A. E., and Brodeur, G. M. (2000) Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. Med. Pediatr. Oncol. 35, 569–572.
Coughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., et al. (1998) Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101, 1441–1452.
Passaniti, A., Taylor, R. M., Pili, R., Guo, R., Long, P. V., Haney, J. A., et al. (1992) A simple quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblastic growth factor. Lab. Invest. 67, 519–528.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Eggert, A., Maris, J.H. (2003). Angiogenic Cytokines. In: Körholz, D., Kiess, W. (eds) Cytokines and Colony Stimulating Factors. Methods in Molecular Biology, vol 215. Humana, Totowa, NJ. https://doi.org/10.1385/1-59259-345-3:117
Download citation
DOI: https://doi.org/10.1385/1-59259-345-3:117
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-1-58829-035-9
Online ISBN: 978-1-59259-345-3
eBook Packages: Springer Protocols